Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function

Biochemical Society Transactions

Volumn 41, Issue 1, 2013, Pages 172-179

  Koole, Cassandra ^a   Pabreja, Kavita ^a   Savage, Emilia E ^a   Wootten, Denise ^a   Furness, Sebastian G B ^a   Miller, Laurence J ^b   Christopoulos, Arthur ^a   Sexton, Patrick M ^a  

^a MONASH UNIVERSITY   (Australia)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Allosteric modulation; Biased signalling; G protein coupled receptor; Glucagon like peptide 1; Glucagon like peptide 1 receptor; Probe dependence

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN;

CONFERENCE PAPER; INSULIN RELEASE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WEIGHT REDUCTION;

ALLOSTERIC REGULATION; AMINO ACID SEQUENCE; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; RECEPTORS, GLUCAGON; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION;

EID: 84873193828     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20120236     Document Type: Conference Paper

References (53)

1. Shaw, J. E., Sicree, R. A. and Zimmet, P. Z. (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87, 4-14
2. Ross, S. A., Gulve, E. A. and Wang, M. (2004) Chemistry and biochemistry of Type 2 diabetes. Chem. Rev. 104, 1255-1282
3. Baggio, L. L. and Drucker, D. J. (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157 (Pubitemid 46711096)
4. Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R. and Creutzfeldt, W. (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with Type-2 diabetes mellitus. J. Clin. Invest. 91, 301-307 (Pubitemid 23037285)
5. Herrmann, C., Goke, R., Richter, G., Fehmann, H. C., Arnold, R. and Goke, B. (1995) Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56, 117-126
6. Reimann, F. (2010) Molecular mechanisms underlying nutrient detection by incretin-secreting cells. Int. Dairy J. 20, 236-242
7. Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L. and Habener, J. F. (1987) Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. U. S. A. 84, 3434-3438 (Pubitemid 17085418)
8. Scrocchi, L. A., Brown, T. J., MaClusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L. and Drucker, D. J. (1996) Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 2, 1254-1258 (Pubitemid 26375413)
9. Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M. and Perfetti, R. (2003) Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144, 5149-5158 (Pubitemid 37476040)
10. Bazarsuren, A., Grauschopf, U., Wozny, M., Reusch, D., Hoffmann, E., Schaefer, W., Panzner, S. and Rudolph, R. (2002) In vitro folding, functional characterization, and disulfide pattern of the extracellular domain of human GLP-1 receptor. Biophys. Chem. 96, 305-318 (Pubitemid 34548241)
11. Runge, S., Thogersen, H., Madsen, K., Lau, J. and Rudolph, R. (2008) Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J. Biol. Chem. 283, 11340-11347
12. Underwood, C. R., Garibay, P., Knudsen, L. B., Hastrup, S., Peters, G. H., Rudolph, R. and Reedtz-Runge, S. (2010) Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. J. Biol. Chem. 285, 723-730
13. Wilmen, A., Goke, B. and Goke, R. (1996) The isolated N-terminal extracellular domain of the glucagon-like peptide-1 (GLP)-1 receptor has intrinsic binding activity. FEBS Lett. 398, 43-47 (Pubitemid 26400339)
14. Al-Sabah, S. and Donnelly, D. (2003) A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors. Br. J. Pharmacol. 140, 339-346 (Pubitemid 37249194)
15. Coopman, K., Wallis, R., Robb, G., Brown, A., Wilkinson, G. F., Timms, D. and Willars, G. B. (2011) Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation. Mol. Endocrinol. 25, 1804-1818
16. Runge, S., Wulff, B. S., Madsen, K., Brauner-Osborne, H. and Knudsen, L. B. (2003) Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity. Br. J. Pharmacol. 138, 787-794 (Pubitemid 36390634)
17. Graziano, M. P., Hey, P. J. and Strader, C. D. (1996) The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity. Recept. Channels 4, 9-17 (Pubitemid 26144632)
18. Chen, Q., Pinon, D. I., Miller, L. J. and Dong, M. (2009) Molecular basis of glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes. J. Biol. Chem. 284, 34135-34144
19. Chen, Q., Pinon, D. I., Miller, L. J. and Dong, M. (2010) Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor: a region critical for biological activity. J. Biol. Chem. 285, 24508-24518
20. Miller, L. J., Chen, Q., Lam, P. C., Pinon, D. I., Sexton, P. M., Abagyan, R. and Dong, M. (2011) Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling. J. Biol. Chem. 286, 15895-15907
21. Lopez de Maturana, R., Treece-Birch, J., Abidi, F., Findlay, J. B. and Donnelly, D. (2004) Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues. Protein Pept. Lett. 11, 15-22 (Pubitemid 38345499)
22. Lopez de Maturana, R. and Donnelly, D. (2002) The glucagon-like peptide-1 receptor binding site for the N-terminus of GLP-1 requires polarity at Asp198 rather than negative charge. FEBS Lett. 530, 244-248 (Pubitemid 35248219)
23. Xiao, Q., Jeng, W. and Wheeler, M. B. (2000) Characterization of glucagon-like peptide-1 receptor-binding determinants. J. Mol. Endocrinol. 25, 321-335 (Pubitemid 32059305)
24. Koole, C., Wootten, D., Simms, J., Miller, L. J., Christopoulos, A. and Sexton, P. M. (2012) Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation. J. Biol. Chem. 287, 3642-3658
25. Koole, C., Wootten, D., Simms, J., Savage, E. E., Miller, L. J., Christopoulos, A. and Sexton, P. M. (2012) Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function. J. Biol. Chem. 287, 3659-3673
26. αo activation. Biochim. Biophys. Acta 1546, 79-86 (Pubitemid 32217804)
27. Montrose-Rafizadeh, C., Avdonin, P., Garant, M. J., Rodgers, B. D., Kole, S., Yang, H., Levine, M. A., Schwindinger, W. and Bernier, M. (1999) Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology 140, 1132-1140 (Pubitemid 29104213)
28. Holz, G. G. (2004) Epac: a new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic β-cell. Diabetes 53, 5-13 (Pubitemid 38044691)
29. Sonoda, N., Imamura, T., Yoshizaki, T., Babendure, J. L., Lu, J. C. and Olefsky, J. M. (2008) β-arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells. Proc. Natl. Acad. Sci. U. S. A. 105, 6614-6619 (Pubitemid 351754555)
30. αs. J. Pharmacol. Exp. Ther. 322, 148-154 (Pubitemid 46956350)
31. Jorgensen, R., Martini, L., Schwartz, T. W. and Elling, C. E. (2005) Characterization of glucagon-like peptide-1 receptor β-arrestin 2 interaction: a high-affinity receptor phenotype. Mol. Endocrinol. 19, 812-823 (Pubitemid 40349451)
32. Quoyer, J., Longuet, C., Broca, C., Linck, N., Costes, S., Varin, E., Bockaert, J., Bertrand, G. and Dalle, S. (2010) GLP-1 mediates anti-apoptotic effect by phosphorylating Bad through a β-arrestin 1-mediated ERK1/2 activation in pancreatic β-cells. J. Biol. Chem. 285, 1989-2002
33. Barnett, A. H. (2009) New treatments in Type 2 diabetes: a focus on the incretin-based therapies. Clin. Endocrinol. (Oxford, U. K.) 70, 343-353
34. Green, B. D. and Flatt, P. R. (2007) Incretin hormone mimetics and analogues in diabetes therapeutics. Best Pract. Res. Clin. Endocrinol. Metab. 21, 497-516 (Pubitemid 350177567)
35. Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thogersen, H., Wilken, M. and Agerso, H. (2000) Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 43, 1664-1669 (Pubitemid 30304999)
36. Christensen, M. and Knop, F. K. (2010) Once-weekly GLP-1 agonists: how do they differ from exenatide and liraglutide? Curr. D iab. Rep. 10, 124-132
37. Hargrove, D. M., Kendall, E. S., Reynolds, J. M., Lwin, A. N., Herich, J. P., Smith, P. A., Gedulin, B. R., Flanagan, S. D., Jodka, C. M., Hoyt, J. A. et al. (2007) Biological activity of AC3174, a peptide analog of exendin-4. Regul. Pept. 141, 113-119 (Pubitemid 46482688)
38. Chae, S. Y., Jin, C. H., Shin, H. J., Youn, Y. S., Lee, S. and Lee, K. C. (2008) Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery. Bioconjugate Chem. 19, 334-341 (Pubitemid 351213867)
39. Parks, M. and Rosebraugh, C. (2010) Weighing risks and benefits of liraglutide: the FDA's review of a new antidiabetic therapy. N. Engl. J. Med. 362, 774-777
40. Olansky, L. (2010) Do incretin drugs for Type 2 diabetes increase the risk of acute pancreatitis? Cleveland Clin. J. Med. 77, 503-505
41. Kenakin, T. (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol. Sci. 16, 232-238
42. Koole, C., Wootten, D., Simms, J., Valant, C., Sridhar, R., Woodman, O. L., Miller, L. J., Summers, R. J., Christopoulos, A. and Sexton, P. M. (2010) Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol. Pharmacol. 78, 456-465
43. Teng, M., Johnson, M. D., Thomas, C., Kiel, D., Lakis, J. N., Kercher, T., Aytes, S., Kostrowicki, J., Bhumralkar, D., Truesdale, L. et al. (2007) Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. Bioorg. Med. Chem. Lett. 17, 5472-5478 (Pubitemid 47391264)
44. Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C. et al. (2007) Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc. Natl. Acad. Sci. U. S. A. 104, 937-942 (Pubitemid 46154715)
45. Irwin, N., Flatt, P. R., Patterson, S. and Green, B. D. (2010) Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6, 7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline. Eur. J. Pharmacol. 628, 268-273
46. Chen, D., Liao, J., Li, N., Zhou, C., Liu, Q., Wang, G., Zhang, R., Zhang, S., Lin, L., Chen, K. et al. (2007) A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc. Natl. Acad. Sci. U. S. A. 104, 943-948 (Pubitemid 46154716)
47. Su, H., He, M., Li, H., Liu, Q., Wang, J., Wang, Y., Gao, W., Zhou, L., Liao, J., Young, A. A. and Wang, M. W. (2008) Boc5, a non-peptidic glucagon-like peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice. PLoS ONE 3, e2892
48. Wootten, D., Simms, J., Koole, C., Woodman, O. L., Summers, R. J., Christopoulos, A. and Sexton, P. M. (2011) Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids. J. Pharmacol. Exp. Ther. 336, 540-550
49. Sloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X., Cox, A. L., Michael, M. D. et al. (2010) Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets. Diabetes 59, 3099-3107
50. Wang, M. W., Liu, Q. and Zhou, C. H. (2010) Non-peptidic glucose-like peptide-1 receptor agonists: aftermath of a serendipitous discovery. Acta Pharmacol. Sin. 31, 1026-1030
51. Keov, P., Sexton, P. M. and Christopoulos, A. (2011) Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology 60, 24-35
52. Willard, F. S., Wootten, D., Showalter, A. D., Savage, E. E., Ficorilli, J., Farb, T. B., Bokvist, K., Alsina-Fernandez, J., Furness, S. G., Christopoulos, A. et al. (2012) Small molecule allosteric modulation of the glucagon-like peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin. Mol. Pharmacol. 82, 1066-1073
53. Wootten, D., Savage, E. E., Valant, C., May, L. T., Sloop, K. W., Ficorilli, J., Showalter, A. D., Willard, F. S., Christopoulos, A. and Sexton, P. (2012) Allosteric modulation of endogenous metabolites as an avenue for drug discovery. Mol. Pharmacol. 82, 281-290